Viyash Scientific Limited — PPTs, 12-08-2026: Investor Presentation

Here's a summary of Viyash Scientific Limited's Q1 FY27 performance, tailored for retail investors:

**Business Performance:** Viyash Scientific reported a strong Q1 FY27 with revenues climbing by 19.5% YoY to ₹9,464 Million. This growth was primarily driven by the Formulations segment, which saw a 33% YoY increase, and robust performance in Emerging Markets (+36% YoY) and India (+63% YoY). EBITDA also saw significant expansion, up 59.2% YoY to ₹2,047 Million, with EBITDA margins improving by 530 bps to 21.6%.

**Growth Drivers or Strategy:** A key strategic move highlighted is the acquisition of Bio For Life in Italy. This acquisition is expected to enhance their presence in the companion animal segment, providing market access and a platform for product launches in Europe.

**Recent Developments:** The acquisition of Bio for Life in Italy is a notable recent development, with the execution of the SPA on July 21, 2026, and expected closing in September 2026.

**Key Financial Metrics:**

* Revenue: ₹9,464 Million (up 19.5% YoY)

* EBITDA: ₹2,047 Million (up 59.2% YoY)

* EBITDA Margin: 21.6%

* Net Debt to EBITDA: 0.1x

**Management Commentary / Outlook:** The company's focus remains on disciplined execution, operational efficiency, and strategic investments to drive sustainable growth. The integration efforts and the strength of the combined entity are key to their forward strategy.